Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Adaptive Biotechnologies Corporation - Common Stock (NQ:ADPT)

17.00 +0.50 (+3.03%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Adaptive Biotechnologies Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
What's Going On With Adaptive Biotechnologies (ADPT) Stock? ↗
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) shares are trading higher Tuesday despite a lack of company-specific news. 
Via Benzinga
News headline image
Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
News headline image
Why Femasys Shares Are Trading Higher By Over 200%; Here Are 20 Stocks Moving Premarket ↗
Gainers Femasys Inc. (NASDAQ: FEMY) shares rose 201% to $1.00 in pre-market trading after the company received FDA 510(k) clearance for FemaSeed, an infertility treatment. 
Via Benzinga
News headline image
Adaptive Announces Launch of Epic Integration for clonoSEQ®
The Adaptive-Epic integration will provide clinicians and patients with easier access to minimal residual disease (MRD) monitoring in blood cancers 
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
A Preview Of Adaptive Biotechnologies's Earnings ↗
 
Via Benzinga
News headline image
Adaptive Biotechnologies's Return On Capital Employed Insights ↗
 
Via Benzinga
News headline image
Adaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
3 Up-and-Coming Biotech Stocks to Put on Your Must-Buy List ↗
Here are some intriguing up-and-coming biotech stocks that may reward risk-tolerant investors with a long-term outlook. 
Via InvestorPlace
News headline image
Cathie Wood Just Sold Shopify -- and Bought These 7 Potentially Explosive Growth Stocks ↗
The Ark Invest CEO continues to trim Shopify holdings to fund some big purchases. 
Via The Motley Fool
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
The popular growth investor keeps adding to some of her favorite stocks. 
Via The Motley Fool
News headline image
Adaptive Biotechnologies: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Cathie Wood Mops Up $8.1M Worth Of Zoom Stock After Q2 Earnings Beat, Sells Nvidia Shares In Excess Of $1M ↗
 
Via Benzinga
Topics Earnings
News headline image
Cathie Wood Sells Shopify Shares Worth $9.2M — Ark Goes Shopping This Dutch Payment Company's Stock Instead ↗
 
Via Benzinga
News headline image
Cathie Wood's Ark Invest Continues To Sell Shopify Shares Amid Q2 Ripples ↗
 
Via Benzinga
News headline image
Cathie Wood's Ark Invest Sells More Tesla Stock — Acquires Shares Of Flying Taxi Company ↗
 
Via Benzinga
News headline image
Cathie Wood's Ark Invest Sells $2.15M Of Tesla Shares Despite Own Bullish Projections ↗
 
Via Benzinga
News headline image
Cathie Wood's Ark Invest Acquires $5.5M of Robinhood Shares Following Platform's First Profitable Quarter ↗
 
Via Benzinga
News headline image
Adaptive Biotechnologies Reports Second Quarter 2023 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Trump Advisor Says Ex-President May Skip Initial Republican Presidential Primary Debates ↗
 
Via Benzinga
News headline image
Cathie Wood's Ark Pours $3.3M More Into This Chipmaker Amid AI Frenzy: Here Are Other Major Monday Trades ↗
 
Via Benzinga
News headline image
Adaptive Biotechnologies to Report Second Quarter Financial Results on August 2, 2023
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Why Shares of Adaptive Biotechnologies Jumped This Week ↗
The company could see its first FDA-approved therapy as early as next year. 
Via The Motley Fool
News headline image
Cathie Wood Goes Bargain-Hunting: 3 Stocks She Just Bought ↗
There are always stocks to buy if you're Ark Invest's ace stock picker. 
Via The Motley Fool
News headline image
Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
There are always stocks to buy if you're Ark Invest's ace stock picker. 
Via The Motley Fool
News headline image
Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
3 Personalized Medicine Stocks to Buy for Long-Time Returns ↗
Personalized medicine is the future of medicine. Here are three personalized medicine stocks to invest in so you don't miss out. 
Via InvestorPlace
News headline image
Adaptive Biotechnologies to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology
The T-Cell Therapy product candidate contains a neoantigen-specific T-cell receptor (TCR) identified and characterized through Adaptive’s TCR discovery platform 
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Reports First Quarter 2023 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.